Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma.

Journal Information

Full Title: Cancer Control

Abbreviation: Cancer Control

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AK has served as a member of scientific advisory boards for Abbvie, Alynylam, BMS, Cota Health, GSK, Janssen, Oncopeptide, Takeda. AK completed this work while a faculty member at UT Southwestern Medical Center; he is now an employee of Janssen. PR has served in Advisory Boards for Kite Pharma, Rafael Pharma and Pharmacyclics LLC. None of the other authors have any relevant conflicts of interest."

Evidence found in paper:

"Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025